Navigation Links
Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
Date:6/1/2009

ients with advanced solid tumors. The objectives of the study are to determine the maximum tolerated dose (MTD) as well as to assess safety and pharmacokinetics. The maximum tolerated dose is not yet defined and accrual to the study continues.

ASCO Poster Information

"A Phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors."

By E. Sausville, L. Garbo, G. J. Weiss, S. Anthony, D. Shkolny, A. V. Yurkovetskiy, C. Bethune, R. J. Fram; University of Maryland, Baltimore, MD; New York Oncology Hematology, Albany, NY; TGen Clinical Research Services, Scottsdale, AZ; Mersana Therapeutics, Inc., Cambridge, MA; Covance Bioanalytical, Madison, WI

    Session: Developmental Therapeutics: Cytotoxic Chemotherapy
    Type: General Poster Session
    Time: Saturday May 30, 2009, 8:00 AM to 12:00 PM
    Location: Level 2, West Hall C

About Fleximer(R)

The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Fleximer(R) technology improves the therapeutic index of existing compounds by uniquely combining biodegradability with "biological stealth" properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized by solubility in water, with stability in common manufacturing procedures.

About Mersana Therapeutics, Inc.

Mersana Therapeutics employs its biodegradable polymer platform (Fleximer(R)) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partner
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
2. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 29, 2015 Research ... addition of the "Biotechnology for the Non-Biotechnologist" ... for the Non-Biotechnologist, ideal for non-Scientists and Scientists ... and potential of biotechnology. Ideal for ... theory, principles, techniques, and potential of biotechnology ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
(Date:7/3/2015)... , July 3, 2015 ... voivat hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Open Innovation in Science" -jatkokoulutusohjelmaan ... Boltzmann Gesellschaftin (LBG) tekemän, kansainvälisiä ... mukaan terveystieteiden kaksi suurinta haastetta ...
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... a historical transformation. Such a dramatic change ... the paper, brewing, automotive and agriculture industries were ... from an agriculture and manufacturing-based state economy to ... Wisconsin now finds itself competing in a global ...
... sat down with Tom Still, the president of the ... tenets of the organization and initiatives Still and others ... Read Part One. , , Wisconsin ... Technology Council has encountered and what are your greatest ...
... in the face of Alzheimers Disease was typical of how it ... but gathered momentum over time. Independence turned to dependence. At the ... a man of 80, but his memory and even his ability ... His body simply forgot how to function. , ,Ive thought of ...
Cached Biology Technology:Educate, innovate and execute: Wisconsins model for success 2Educate, innovate and execute: Wisconsins model for success 3WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 2WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 3WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 4The passing of Ronald Reagan, and other Americans, is a reminder of the promise of stem-cell research 2
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market announces that ... featured segment on "Money on the Mark", scheduled to air ... June 20 th . The ... be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... have hypothesized that the fetus can be exposed to ... the mother has been exposed, and this may have ... eczema and asthma) later in an infant’s life. However ... to detect antigen-specific T cells in cord blood. Recently, ...
... discovered 24 species believed to be new to science, ... amphibians, fish and insects. , Presented in a report ... led by Conservation International’s Rapid Assessment Program (RAP) and ... exploring unknown regions such as Suriname’s rainforest to assess ...
... dormant bacterial spores, researchers have revealed through atomic force ... cell wall that accompany the transformation from a spore ... Bacillus (rod-shaped bacteria) cells initiate a series of genetic, ... of metabolically dormant spores. They can remain dormant for ...
Cached Biology News:Researchers find 24 species believed new to science in Suriname rainforest 2Researchers track how spores break out of dormant state 2
... culture systems provide an integrated ... for staining and imaging. Each ... preassembled with standard optical-quality coverslips ... entire system is provided sterile ...
nuclear cap binding protein subunit 1, 80kDa, mRNA...
GOAT ANTI SLI...
RABBIT ANTI RAT AQUAPORIN 5...
Biology Products: